abstract: 1. CPI-17 has recently been identified as a novel protein in vascular smooth muscle. In vitro , its phosphorylation and thiophosphorylation by @entity1 ( @entity1 ) specifically inhibits the type 1 class of protein phosphatases, including myosin light chain (MLC) phosphatase. 2. Both of the phosphorylated CPI-17 states dose-dependently potentiated submaximal contractions at constant [ @entity0 ] in beta-escin-permeabilized and Triton X-100-demembranated arterial smooth muscle, but produced no effect in intact and less intensely permeabilized (alpha-toxin) tissue. Thiophosphorylated CPI-17 (tp-CPI) induced large contractions even under @entity0 -free conditions and decreased @entity0 EC50 by more than an order of magnitude. Unphosphorylated CPI-17 produced minimal but significant effects. 3. tp-CPI substantially increased the steady-state MLC phosphorylation to @entity0 ratios in beta-escin preparations. 4. tp-CPI affected the kinetics of contraction and relaxation and of MLC phosphorylation and dephosphorylation in such a manner that indicates its major physiological effect is to inhibit MLC phosphatase. 5. Results from use of specific inhibitors in concurrence with tp-CPI repudiate the involvement of general G proteins, @entity2 or @entity1 itself in the @entity0 sensitization by tp-CPI. 6. Our results indicate that phosphorylation of CPI-17 by @entity1 stimulates binding of CPI-17 to and subsequent inhibition of MLC phosphatase. This implies that CPI-17 accounts largely for the heretofore unknown signalling pathway between @entity1 and inhibited MLC phosphatase.

title: Possible involvement of the novel CPI-17 protein in XXXX signal transduction of rabbit arterial smooth muscle.

answer: @entity1


abstract: 1. This study was performed to test the hypothesis that inflammatory cytokines are produced in skeletal muscle in response to prolonged intense exercise. Muscle biopsies and blood samples were collected from runners before, immediately after, and 2 h after a marathon race. 2. The concentration of @entity3 protein in plasma increased from 1.5 +/- 0.7 to 94.4 +/- 12.6 pg ml-1 immediately post-exercise and to 22.1 +/- 3.8 pg ml-1 2 h post-exercise. @entity4 ( @entity4 ) protein in plasma increased from 123 +/- 23 to 2795 +/- 551 pg ml-1, and increased further to 4119 +/- 527 pg ml-1 2 h post-exercise. 3. The comparative polymerase chain reaction technique was used to evaluate mRNA for @entity3 , @entity4 , @entity5 and @entity0 @entity1 factor ( @entity2 in skeletal muscle and blood mononuclear cells (BMNC) (n = 8). Before exercise, mRNA for @entity3 could not be detected either in muscle or in BMNC, and was only detectable in muscle biopsies (5 out of 8) after exercise. Increased amounts of mRNA for @entity4 were found in two muscle biopsies and five BMNC samples, and increased amounts of @entity5 mRNA were found in one muscle and four BMNC samples after exercise. @entity2 mRNA was not detected in any samples. 4. This study suggests that exercise-induced destruction of muscle fibres in skeletal muscles may trigger local production of @entity3 , which stimulates the production of @entity4 from circulating BMNC.

title: Evidence that XXXX is produced in human skeletal muscle during prolonged running.

answer: @entity3


abstract: OBJECTIVES: To reduce @entity2 , we developed a new technique of catheter implantation, combining a presternal catheter with the Moncrief technique. METHODS: The presternal catheter, consisting of 2 catheters joined by a @entity3 extender, was surgically implanted. Its end was left embedded in the presternal wall. A few weeks after implantation, the embedded subcutaneous catheter was exteriorized, exiting in the 4th intercostal space, and @entity1 ( @entity1 ) was commenced. RESULTS: Using the new technique, 9 catheters were implanted (3 in @entity0 and 6 in @entity0 ). Exteriorization was performed 30.6 +/- 14.3 days after implantation of the catheter. Total observation period was 70 @entity0 -months. Average hospitalization was 4.4 +/- 1.3 days for catheter implantation, and 2.6 +/- 2.6 days for exteriorization. Peritoneal dialysis commenced on the day of exteriorization with an exchange volume of 1.8 +/- 0.3 L, using 4 exchanges daily. During the observation period, none of the @entity0 experienced a @entity4 or dialysate leak. One non infectious complication was observed (a catheter wrapped in omentum). CONCLUSIONS: Our approach of combining a presternal catheter and the Moncrief technique had some advantages not only in regard to @entity4 and dialysate leakage, but also in regard to quality of life and hospitalization for the @entity0 .

title: Implantation of presternal catheter using Moncrief technique: aiming for fewer XXXX .

answer: @entity2


abstract: @entity8 is widely endemic in Asia. @entity0 's behaviour and climatic changes greatly influenced the occurrence of the disease. Increasing prevalences of @entity8 have been reported from some Asian countries and may coincide with the widespread use of @entity6 antibiotics or to improve diagnostic facilities and/or more urbanisation into rural areas. Many cases acquired in Asia surfaced in Europe and America. The disease probably is overlooked among paediatric @entity0 . Most @entity0 with @entity8 present with acute fever of unknown origin (acute FUO). Eschars are rare among Southeast Asian @entity0 . Complications usually develop after the first week of illness. The complications include @entity1 , @entity7 , @entity2 and @entity3 . Improved serologic and molecular diagnostic tests are now available. Although drug-resistant strain of @entity9 has been reported, the infection usually responds to simple but unpopular drugs such as @entity5 or @entity4 .

title: XXXX in the Western Pacific region.

answer: @entity8


abstract: PURPOSE: The feasibility of using hydrophobicity measurements as screens for intracellular availability in T-cells or intestinal permeability in Caco-2 cells was examined. METHODS: T-cell experiments: Cells were counted, collected, then incubated with drug solution at 37 degrees C. At selected time intervals, uptake was quenched by transferring a sample into oil, followed by rinsing, lysis of cells, protein precipitation and analysis by HPLC. Caco-2 cell experiments: Cells were grown on plastic dishes for 7-10 d, then rinsed and incubated with drug solution at 37 degrees C. Uptake was quenched, cells were lysed, protein precipitated and drug was analyzed by HPLC. IAM chromatography: Stock solutions were injected onto an IAM column for HPLC. Mobile phase consisted of varying amounts of @entity1 in buffer (pH 7.4). The capacity factor, k'IAM, was calculated using @entity2 to measure the void volume and was obtained by extrapolation to pure buffer. RESULTS: Nine @entity0 protease inhibitors were studied for uptake by CEM T-cell suspensions or Caco-2 cell monolayers. Capacity factors (log) between IAM and C-18 columns were positively correlated for this series. Caco-2 uptake rates correlated well with T-cell uptake rates when normalized by protein mass. Single-variable regression using IAM or C-18 columns was acceptable for analysis of T-cell data. Correlation coefficients between T-cell uptake and log k'IAM or log k'C-18 were not improved with multivariable regression. Correlation between Caco-2 uptake and log k'IAM was enhanced when molecular weight and @entity3 -bonding potential were included in multivariable regression analysis (from r2 of 0.39 to 0.91). Correlations obtained using log k'IAM, log k'C-18 or log distribution coefficient (log D) were comparable when regressed against Caco-2 uptake using this approach. Calculated log partition coefficient (ClogP) provided the poorest correlation in the multivariable analysis (r2=0.57 for T-cell uptake and r2=0.71 for Caco-2 cell uptake). CONCLUSIONS: Uptake of @entity0 protease inhibitors by T-cell suspensions or Caco-2 cell monolayers was positively correlated. Uptake by T-cell suspensions was adequately described by hydrophobicity alone. Description of uptake by Caco-2 cell monolayers required multivariable regression analysis in which molecular weight and @entity3 bonding were included. Experimental measures of hydrophobicity (log k'IAM, log k'C-18 and log D) were superior to ClogP in the correlation analysis.

title: Hydrophobicity of XXXX protease inhibitors by immobilized artificial membrane chromatography: application and significance to drug transport.

answer: @entity0


abstract: PURPOSE: To evaluate percutaneous embolotherapy in the treatment of @entity2 . MATERIALS AND METHODS: Twenty-one @entity0 who underwent attempted percutaneous embolization for @entity2 between 1982 and 1997 were retrospectively studied. @entity3 sites included jejunum (n = 4), ileum (n = 4), cecum (n = 4), and the remaining colon (n = 9). RESULTS: Embolization was not technically possible in four @entity0 (19%). Hemostasis was achieved in 15 @entity0 (71%) with prolonged hemostasis in 10 (48%). All @entity4 distal to the cecum resulted in prolonged hemostasis. Three of four @entity0 with @entity3 had recurrent @entity3 after apparent successful embolization. Only one of four cecal @entity4 achieved prolonged cessation of @entity3 . No @entity1 complications were identified. CONCLUSION: Based on these data, it would appear that the risk of @entity1 / @entity5 in the lower gastrointestinal tract may not be as high as has been suggested. Two regions (cecum and proximal jejunum) were associated with poor results, suggesting these areas may not be as responsive to embolotherapy as other sites in the lower gastrointestinal tract.

title: Percutaneous embolotherapy of XXXX .

answer: @entity2


abstract: @entity6 , a novel aminotetralin @entity5 D2 agonist, was shown to effectively reverse @entity2 in nine dopa/agonist-responsive @entity1 @entity0 . The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti- @entity1 effect was seen within minutes of the initiation of the infusion and was absent within 90 minutes of cessation of the infusion. The short elimination half-life of @entity6 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary. The drug would be useful in situations where oral medication is not feasible or is associated with erratic absorption. The @entity0 tolerated the drug well. Dose escalation load was limited by @entity3 and @entity4 . It should be noted that the doses were increased until these symptoms occurred, but therapeutic effects were noted well before the side effects occurred. Using a modified Columbia scale, maximum improvement consisted of a 27-95% drop in score. Maximum response was obtained at infusion rates varying from 2-16 microg/kg per hour and at blood levels of 0.11-1.49 microg/mL.

title: @entity6 , a novel soluble XXXX D2 agonist in the treatment of @entity2 .

answer: @entity5


abstract: @entity6 , a novel aminotetralin @entity5 D2 agonist, was shown to effectively reverse @entity2 in nine dopa/agonist-responsive @entity1 @entity0 . The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti- @entity1 effect was seen within minutes of the initiation of the infusion and was absent within 90 minutes of cessation of the infusion. The short elimination half-life of @entity6 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary. The drug would be useful in situations where oral medication is not feasible or is associated with erratic absorption. The @entity0 tolerated the drug well. Dose escalation load was limited by @entity3 and @entity4 . It should be noted that the doses were increased until these symptoms occurred, but therapeutic effects were noted well before the side effects occurred. Using a modified Columbia scale, maximum improvement consisted of a 27-95% drop in score. Maximum response was obtained at infusion rates varying from 2-16 microg/kg per hour and at blood levels of 0.11-1.49 microg/mL.

title: @entity6 , a novel soluble @entity5 D2 agonist in the treatment of XXXX .

answer: @entity2


abstract: @entity6 , a novel aminotetralin @entity5 D2 agonist, was shown to effectively reverse @entity2 in nine dopa/agonist-responsive @entity1 @entity0 . The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti- @entity1 effect was seen within minutes of the initiation of the infusion and was absent within 90 minutes of cessation of the infusion. The short elimination half-life of @entity6 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary. The drug would be useful in situations where oral medication is not feasible or is associated with erratic absorption. The @entity0 tolerated the drug well. Dose escalation load was limited by @entity3 and @entity4 . It should be noted that the doses were increased until these symptoms occurred, but therapeutic effects were noted well before the side effects occurred. Using a modified Columbia scale, maximum improvement consisted of a 27-95% drop in score. Maximum response was obtained at infusion rates varying from 2-16 microg/kg per hour and at blood levels of 0.11-1.49 microg/mL.

title: XXXX , a novel soluble @entity5 D2 agonist in the treatment of @entity2 .

answer: @entity6


abstract: OBJECTIVE: This study examined the effects of varying the energy density (ED) of high @entity2 (HC) diets on food and energy intake (EI), subjective hunger and body weight in @entity0 . DESIGN: Randomised cross-over design. Subjects were each studied twice during 14 d, throughout which they had ad libitum access to one of two covertly-manipulated diets. SUBJECTS AND METHODS: Six healthy @entity0 (mean age (s.d.)=32.17 y s.d. (5.26 y), mean weight=69.74 kg s.d. (2.75 kg), mean height=1.76 m s.d. (0.05 m), body mass index (BMI)=22.57 (2.2) kg/m2) were studied. The fat, @entity2 ( @entity1 ) and protein content (as % energy) and ED of each diet were 21:66:13% and 357 kJ/100 g, (low-energy density (LED)) or 22:66:12% and 629 kJ/100 g ( @entity3 ( @entity3 )). A medium fat diet was provided at maintenance (1.6 x BMR, MF for 2 d) before each ad libitum period. Subjects could alter the amount, but not the composition of foods eaten. RESULTS: Mean EI was 8.67 and 14.82 MJ/d on the LED and @entity3 diets, respectively. Subjects felt significantly more hungry on the LED diet, than on the @entity3 diet (F(1,160)38.28; P < 0.001) and found the diets to be similarly pleasant (72.72 mm vs 71.54 mm (F(1,392)0.31; P = 0.579)). Mean body weight decreased on the LED diet at a rate of 0.1 kg/d and increased at 0.06 kg/d on the @entity3 diet (F(1,131)86.60; P < 0.001), giving total weight changes of -1.41 kg and +0.84 kg, respectively, both of which were significantly different from zero (P < 0.01). CONCLUSION: Excess EI is possible on HC, @entity3 diets, at least under conditions where diet selection is precluded. Comparison of these results with previous studies, which altered ED using fat, suggests that @entity1 may be a better cue for hunger than fat.

title: Covert manipulation of energy density of high XXXX diets in 'pseudo free-living' @entity0 .

answer: @entity2


abstract: OBJECTIVE: This study examined the effects of varying the energy density (ED) of high @entity2 (HC) diets on food and energy intake (EI), subjective hunger and body weight in @entity0 . DESIGN: Randomised cross-over design. Subjects were each studied twice during 14 d, throughout which they had ad libitum access to one of two covertly-manipulated diets. SUBJECTS AND METHODS: Six healthy @entity0 (mean age (s.d.)=32.17 y s.d. (5.26 y), mean weight=69.74 kg s.d. (2.75 kg), mean height=1.76 m s.d. (0.05 m), body mass index (BMI)=22.57 (2.2) kg/m2) were studied. The fat, @entity2 ( @entity1 ) and protein content (as % energy) and ED of each diet were 21:66:13% and 357 kJ/100 g, (low-energy density (LED)) or 22:66:12% and 629 kJ/100 g ( @entity3 ( @entity3 )). A medium fat diet was provided at maintenance (1.6 x BMR, MF for 2 d) before each ad libitum period. Subjects could alter the amount, but not the composition of foods eaten. RESULTS: Mean EI was 8.67 and 14.82 MJ/d on the LED and @entity3 diets, respectively. Subjects felt significantly more hungry on the LED diet, than on the @entity3 diet (F(1,160)38.28; P < 0.001) and found the diets to be similarly pleasant (72.72 mm vs 71.54 mm (F(1,392)0.31; P = 0.579)). Mean body weight decreased on the LED diet at a rate of 0.1 kg/d and increased at 0.06 kg/d on the @entity3 diet (F(1,131)86.60; P < 0.001), giving total weight changes of -1.41 kg and +0.84 kg, respectively, both of which were significantly different from zero (P < 0.01). CONCLUSION: Excess EI is possible on HC, @entity3 diets, at least under conditions where diet selection is precluded. Comparison of these results with previous studies, which altered ED using fat, suggests that @entity1 may be a better cue for hunger than fat.

title: Covert manipulation of energy density of high @entity2 diets in 'pseudo free-living' XXXX .

answer: @entity0


abstract: Gathering knowledge about the molecular events during preimplantation development is one of the most important challenges in @entity1 ( @entity1 ). The @entity3 ( @entity3 ) system has been shown to be intimately involved in embryonic implantation. The aim of our study was to detect the major components of the @entity3 system in single blastomeres from @entity0 preimplantation embryos and to relate our findings to the further development of the biopsied embryos in vitro. Single blastomeres were removed from morphologically normal embryos obtained from dipronuclear zygotes and examined by reverse transcription (RT)-nested polymerase chain reaction (PCR). Expression of @entity2 (external standard), @entity5 , @entity4 ( @entity4 ) and @entity6 ( @entity6 ) type I mRNA were related to embryonic development and @entity1 outcome. Blastomeres from 12 embryos were examined: @entity2 and @entity6 type I mRNA were detected in all blastomeres (100%) whereas @entity5 could be detected in only nine of the blastomeres (75%). @entity4 was expressed in only two (17%) of the blastomeres and those were simultaneously positive for @entity5 . Both @entity4 positive embryos were arrested in development before reaching blastocyst stage. Five embryos (three of them @entity5 mRNA positive and two @entity5 mRNA negative) were transferred as blastocysts; none of the transfers resulted in a pregnancy. We postulate that embryos expressing @entity4 mRNA in a detectable amount appear more likely to be arrested in early developmental stages.

title: Expression of XXXX system mRNA in single blastomeres from @entity0 preimplantation embryos.

answer: @entity3


abstract: Gathering knowledge about the molecular events during preimplantation development is one of the most important challenges in @entity1 ( @entity1 ). The @entity3 ( @entity3 ) system has been shown to be intimately involved in embryonic implantation. The aim of our study was to detect the major components of the @entity3 system in single blastomeres from @entity0 preimplantation embryos and to relate our findings to the further development of the biopsied embryos in vitro. Single blastomeres were removed from morphologically normal embryos obtained from dipronuclear zygotes and examined by reverse transcription (RT)-nested polymerase chain reaction (PCR). Expression of @entity2 (external standard), @entity5 , @entity4 ( @entity4 ) and @entity6 ( @entity6 ) type I mRNA were related to embryonic development and @entity1 outcome. Blastomeres from 12 embryos were examined: @entity2 and @entity6 type I mRNA were detected in all blastomeres (100%) whereas @entity5 could be detected in only nine of the blastomeres (75%). @entity4 was expressed in only two (17%) of the blastomeres and those were simultaneously positive for @entity5 . Both @entity4 positive embryos were arrested in development before reaching blastocyst stage. Five embryos (three of them @entity5 mRNA positive and two @entity5 mRNA negative) were transferred as blastocysts; none of the transfers resulted in a pregnancy. We postulate that embryos expressing @entity4 mRNA in a detectable amount appear more likely to be arrested in early developmental stages.

title: Expression of @entity3 system mRNA in single blastomeres from XXXX preimplantation embryos.

answer: @entity0


abstract: BACKGROUND: Cranioplasty encompasses various cranial reconstruction techniques that are used following craniectomy due to @entity1 or @entity2 . Despite classical infectious signs, symptoms, and radiologic findings, however, the diagnosis of @entity4 following cranioplasty can be elusive, with the potential to result in definitive treatment delay. We sought to determine if @entity3 or @entity5 at presentation were indicative of @entity4 , as well as to identify any factors that may limit its applicability. METHODS: Following institutional review board approval, a retrospective cohort of 239 @entity0 who underwent cranioplasty following craniectomy for @entity1 or @entity2 was established from 2001-2011 at a single center (Massachusetts General Hospital). Analysis was then focused on those who developed a @entity4 , as defined by either frank intra-operative purulence or positive intra-operative cultures, and subsequently underwent operative management. RESULTS: In 27 total cases of @entity4 , only two had a @entity3 and four had @entity5 at presentation. This yielded a false-negative rate for @entity3 of 92.6% and for @entity5 of 85.2%. In regard to infectious etiology, 22 (81.5%) cases generated positive intra-operative cultures, with @entity6 being the most common organism isolated. Median interval to @entity4 was 99 days from initial cranioplasty to time of infectious presentation, and average follow-up was 3.4 years. CONCLUSIONS: The utilization of @entity3 and elevated white blood cell count in the diagnosis of post-cranioplasty @entity4 is associated with a high false-negative rate, making the absence of these features insufficient to exclude the diagnosis of @entity4 .

title: The Absence of Fever or XXXX Does Not Exclude Infection Following Cranioplasty.

answer: @entity5


abstract: UNASSIGNED: @entity6 ( @entity6 ) is an increasingly common cause of @entity1 and systemic @entity5 . While @entity8 has been the mainstay of @entity1 prevention in @entity0 with @entity6 , newer novel oral anticoagulant medications are now available. @entity9 , a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over @entity8 , predominantly due to its predictable pharmacokinetics across wide @entity0 populations. It requires no coagulation monitoring, and only two different doses are needed (20  mg daily for @entity0 with normal renal function and 15  mg daily in those with @entity2 ). A large randomized trial (ROCKET @entity6 ) has shown non-inferiority to @entity8 for preventing @entity1 or systemic @entity5 in the per-protocol population and superiority to @entity8 in the on-treatment safety population. Several subanalyses confirm that the treatment effect of @entity9 is consistent across different @entity0 subgroups, including those with @entity2 . The tolerability of @entity9 appears similar to that of @entity8 , with comparable overall bleeding rates in clinical trials. In ROCKET @entity6 , significantly lower rates of fatal and @entity4 were seen with @entity9 , while lower rates of @entity3 were seen with @entity8 . Important contraindications to @entity9 include valvular @entity6 , the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and @entity7 clearance <30  ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with @entity8 , potentially decreasing the large burden of care associated with @entity1 secondary to @entity6 . Overall, @entity9 offers a useful alternative to @entity8 for @entity1 prevention in @entity0 with @entity6 .

title: XXXX in the Prevention of @entity1 in @entity0 with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET @entity6 Trial and Its Subanalyses.

answer: @entity9


abstract: UNASSIGNED: @entity6 ( @entity6 ) is an increasingly common cause of @entity1 and systemic @entity5 . While @entity8 has been the mainstay of @entity1 prevention in @entity0 with @entity6 , newer novel oral anticoagulant medications are now available. @entity9 , a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over @entity8 , predominantly due to its predictable pharmacokinetics across wide @entity0 populations. It requires no coagulation monitoring, and only two different doses are needed (20  mg daily for @entity0 with normal renal function and 15  mg daily in those with @entity2 ). A large randomized trial (ROCKET @entity6 ) has shown non-inferiority to @entity8 for preventing @entity1 or systemic @entity5 in the per-protocol population and superiority to @entity8 in the on-treatment safety population. Several subanalyses confirm that the treatment effect of @entity9 is consistent across different @entity0 subgroups, including those with @entity2 . The tolerability of @entity9 appears similar to that of @entity8 , with comparable overall bleeding rates in clinical trials. In ROCKET @entity6 , significantly lower rates of fatal and @entity4 were seen with @entity9 , while lower rates of @entity3 were seen with @entity8 . Important contraindications to @entity9 include valvular @entity6 , the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and @entity7 clearance <30  ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with @entity8 , potentially decreasing the large burden of care associated with @entity1 secondary to @entity6 . Overall, @entity9 offers a useful alternative to @entity8 for @entity1 prevention in @entity0 with @entity6 .

title: @entity9 in the Prevention of XXXX in @entity0 with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET @entity6 Trial and Its Subanalyses.

answer: @entity1


abstract: UNASSIGNED: @entity6 ( @entity6 ) is an increasingly common cause of @entity1 and systemic @entity5 . While @entity8 has been the mainstay of @entity1 prevention in @entity0 with @entity6 , newer novel oral anticoagulant medications are now available. @entity9 , a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over @entity8 , predominantly due to its predictable pharmacokinetics across wide @entity0 populations. It requires no coagulation monitoring, and only two different doses are needed (20  mg daily for @entity0 with normal renal function and 15  mg daily in those with @entity2 ). A large randomized trial (ROCKET @entity6 ) has shown non-inferiority to @entity8 for preventing @entity1 or systemic @entity5 in the per-protocol population and superiority to @entity8 in the on-treatment safety population. Several subanalyses confirm that the treatment effect of @entity9 is consistent across different @entity0 subgroups, including those with @entity2 . The tolerability of @entity9 appears similar to that of @entity8 , with comparable overall bleeding rates in clinical trials. In ROCKET @entity6 , significantly lower rates of fatal and @entity4 were seen with @entity9 , while lower rates of @entity3 were seen with @entity8 . Important contraindications to @entity9 include valvular @entity6 , the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and @entity7 clearance <30  ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with @entity8 , potentially decreasing the large burden of care associated with @entity1 secondary to @entity6 . Overall, @entity9 offers a useful alternative to @entity8 for @entity1 prevention in @entity0 with @entity6 .

title: @entity9 in the Prevention of @entity1 in @entity0 with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET XXXX Trial and Its Subanalyses.

answer: @entity6


abstract: UNASSIGNED: @entity6 ( @entity6 ) is an increasingly common cause of @entity1 and systemic @entity5 . While @entity8 has been the mainstay of @entity1 prevention in @entity0 with @entity6 , newer novel oral anticoagulant medications are now available. @entity9 , a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over @entity8 , predominantly due to its predictable pharmacokinetics across wide @entity0 populations. It requires no coagulation monitoring, and only two different doses are needed (20  mg daily for @entity0 with normal renal function and 15  mg daily in those with @entity2 ). A large randomized trial (ROCKET @entity6 ) has shown non-inferiority to @entity8 for preventing @entity1 or systemic @entity5 in the per-protocol population and superiority to @entity8 in the on-treatment safety population. Several subanalyses confirm that the treatment effect of @entity9 is consistent across different @entity0 subgroups, including those with @entity2 . The tolerability of @entity9 appears similar to that of @entity8 , with comparable overall bleeding rates in clinical trials. In ROCKET @entity6 , significantly lower rates of fatal and @entity4 were seen with @entity9 , while lower rates of @entity3 were seen with @entity8 . Important contraindications to @entity9 include valvular @entity6 , the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and @entity7 clearance <30  ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with @entity8 , potentially decreasing the large burden of care associated with @entity1 secondary to @entity6 . Overall, @entity9 offers a useful alternative to @entity8 for @entity1 prevention in @entity0 with @entity6 .

title: @entity9 in the Prevention of @entity1 in XXXX with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET @entity6 Trial and Its Subanalyses.

answer: @entity0


abstract: UNASSIGNED: Prevalence of @entity1 is increased in @entity0 with @entity2 . However, it is not known how @entity3 correlates with @entity2 . This study investigated the association between @entity2 and @entity3 compared with @entity0 without @entity2 within the population-based Rotterdam Study. All @entity0 were screened for @entity3 using transient elastography. Liver stiffness >   9.5 kPa suggested advanced @entity3 . Psoriasis was identified using a validated algorithm. A total of 1,535 @entity0 were included (mean age        standard deviation 70.5        7.9 years; 50.8% female; median body mass index 26.4 kg/m2 (interquartile range 24.2-28.9)) of whom 74 (4.7%) had @entity2 . Prevalence of advanced @entity3 was 8.1% in @entity2 @entity0 compared with 3.6% in the reference group (p   =   0.05). The risk of advanced @entity3 in @entity2 @entity0 remained comparable after adjustment for demographics, lifestyle characteristics and laboratory findings (odds ratio 2.57 (95% confidence interval 1.00-6.63). This study suggests that elderly @entity0 with @entity2 are twice as likely to have advanced @entity3 irrespective of common risk factors.

title: Increased Prevalence of Advanced XXXX in @entity0 with Psoriasis: A Cross-sectional Analysis from the Rotterdam Study.

answer: @entity3


abstract: UNASSIGNED: Prevalence of @entity1 is increased in @entity0 with @entity2 . However, it is not known how @entity3 correlates with @entity2 . This study investigated the association between @entity2 and @entity3 compared with @entity0 without @entity2 within the population-based Rotterdam Study. All @entity0 were screened for @entity3 using transient elastography. Liver stiffness >   9.5 kPa suggested advanced @entity3 . Psoriasis was identified using a validated algorithm. A total of 1,535 @entity0 were included (mean age        standard deviation 70.5        7.9 years; 50.8% female; median body mass index 26.4 kg/m2 (interquartile range 24.2-28.9)) of whom 74 (4.7%) had @entity2 . Prevalence of advanced @entity3 was 8.1% in @entity2 @entity0 compared with 3.6% in the reference group (p   =   0.05). The risk of advanced @entity3 in @entity2 @entity0 remained comparable after adjustment for demographics, lifestyle characteristics and laboratory findings (odds ratio 2.57 (95% confidence interval 1.00-6.63). This study suggests that elderly @entity0 with @entity2 are twice as likely to have advanced @entity3 irrespective of common risk factors.

title: Increased Prevalence of Advanced @entity3 in XXXX with Psoriasis: A Cross-sectional Analysis from the Rotterdam Study.

answer: @entity0


abstract: PURPOSE: Despite the prevalence of @entity9 in neuroimaging and its link to @entity5 , @entity2 , and @entity4 , the exact pathogenesis is still unclear. While some have postulated a link between @entity7 and @entity9 , the exact relationship between the two common clinical findings is unknown. To determine the link between @entity3 and @entity9 , we performed a systematic review of interhemispheric differences in @entity1 in @entity0 with @entity7 . METHODS: We performed a comprehensive literature search in multiple electronic databases evaluating the association of carotid artery and @entity1 using both subjective and volumetric assessment of white matter burden. The included studies examined @entity0 with at least 30   % @entity6 for white matter burden both ipsilateral and contralateral to the site of @entity7 . RESULTS: Of the 2920 manuscripts screened, five were included in the systematic review. One study used a volumetric analysis of the white matter burden and the others used various subjective methods. Four studies found no statistically significant relationship between carotid @entity1 and one study found a significantly higher amount of @entity1 ipsilateral to @entity6 . CONCLUSIONS: The mixed results in degree of @entity9 in @entity0 with @entity7 indicate that no definite relationship can be established based on the existing literature. Given the complex nature of @entity7 , including increased risk with certain plaque components, the exact relationship requires further investigation with more @entity8 .

title: Hemispheric Differences in XXXX in @entity0 with Carotid Artery Stenosis: A Systematic Review.

answer: @entity9


abstract: PURPOSE: Despite the prevalence of @entity9 in neuroimaging and its link to @entity5 , @entity2 , and @entity4 , the exact pathogenesis is still unclear. While some have postulated a link between @entity7 and @entity9 , the exact relationship between the two common clinical findings is unknown. To determine the link between @entity3 and @entity9 , we performed a systematic review of interhemispheric differences in @entity1 in @entity0 with @entity7 . METHODS: We performed a comprehensive literature search in multiple electronic databases evaluating the association of carotid artery and @entity1 using both subjective and volumetric assessment of white matter burden. The included studies examined @entity0 with at least 30   % @entity6 for white matter burden both ipsilateral and contralateral to the site of @entity7 . RESULTS: Of the 2920 manuscripts screened, five were included in the systematic review. One study used a volumetric analysis of the white matter burden and the others used various subjective methods. Four studies found no statistically significant relationship between carotid @entity1 and one study found a significantly higher amount of @entity1 ipsilateral to @entity6 . CONCLUSIONS: The mixed results in degree of @entity9 in @entity0 with @entity7 indicate that no definite relationship can be established based on the existing literature. Given the complex nature of @entity7 , including increased risk with certain plaque components, the exact relationship requires further investigation with more @entity8 .

title: Hemispheric Differences in @entity9 in XXXX with Carotid Artery Stenosis: A Systematic Review.

answer: @entity0


abstract: A 22-year-old @entity0 presented with a growing lump on the fifth metatarsal of the right foot. Radiographically, the lesion was a calcified mass stuck on to the bone. The T2-weighted magnetic resonance images showed heterogeneity in intensity. A @entity1 was suspected and an excisional biopsy was done. The lesion was composed of a cartilaginous cap and bone tissue. Histological examination revealed characteristic features of bizarre @entity3 (BPOP), such as hypercellularity, a blue tinctorial quality in the osteocartilaginous interfaces, and a scattering of binucleated or bizarre enlarged chondrocytes. Immunohistochemically, basic fibroblast growth factor was expressed in nearly all chondrocytes within the cartilaginous cap, while @entity2 was expressed only in enlarged chondrocytes near the osteocartilaginous interfaces. Reverse transcription-polymerase chain reaction detected @entity4 transcripts in the tissue of the cartilaginous cap. These findings indicate that the processes occurring in BPOP are similar to those occurring in endochondral ossification in the growth plate, and they support the concept that BPOP is a reparative process. BPOP is a rare tumorous lesion of the bone and is occasionally confused with other benign or malignant conditions. Thus, it is important to consider the clinical, radiographical and the gross histological features of the lesion when making a diagnosis.

title: Bizarre XXXX (Nora's lesion) of the foot.

answer: @entity3


abstract: BACKGROUND: Laboratory and field studies showed that repellent, irritant and toxic actions of common public health insecticides reduce @entity0 -vector contact and thereby interrupt disease transmission. One of the more effective strategies to reduce disease risk involves the use of long-lasting treated bednets. However, development of insecticide resistance in mosquito populations makes it imperative to find alternatives to these insecticides. Our previous study identified four essential oils as alternatives to @entity3 : Thymus vulgaris, Cymbopogon winterianus, Cuminum cyminum, Cinnamomum zeylanicum. The objectives of this study were to identify active compounds of these essential oils, to characterize their biological activity, and to examine their potential as a treatment for bednets. METHODS: We evaluated the electrophysiological, behavioural (repellency, irritancy) and toxic effects of the major compounds of these oils against @entity4 'Kisumu'. RESULTS: @entity5 elicited the strongest responses and @entity2 the weakest responses in electroantennogram (EAG) trials. However, EAG responses did not correlate consistently with results of behavioral assays. In behavioral and @entity1 studies, several of the single compounds did exhibit repellency, irritancy or @entity1 in An. gambiae; however, the activity of essential oils did not always correlate with activity expected from the major components. On the contrary, the biological activity of essential oils appeared complex, suggesting interactions between individual compounds and the insect under study. Data also indicated that the three effects appeared independent, suggesting that repellency mechanism(s) may differ from mechanisms of irritancy and @entity1 . CONCLUSIONS: Based on the bioassays reported here, some of the compounds merit consideration as alternative bednet treatments.

title: Electrophysiological and behavioral characterization of bioactive compounds of the Thymus vulgaris, Cymbopogon winterianus, Cuminum cyminum and Cinnamomum zeylanicum essential oils against XXXX and prospects for their use as bednet treatments.

answer: @entity4


abstract: UNASSIGNED: Dengue is a mosquito-borne @entity3 that afflicts millions of individuals worldwide every year. Infection by any of the four serotypes can result in a spectrum of disease severity. We investigated the impact of variants of interferon regulated innate immunity genes with a potent anti-viral effect, on the outcome of @entity1 . We compared the effect of OAS gene family variants on two @entity2 virus (DENV) serotypes in cell culture. While both @entity6 - @entity5 and p46 showed antiviral activity against DENV-2, only @entity6 - @entity5 presented anti-DENV-1 activity. Conversely, whereas both @entity4 _S381 and R381 variants were able to block DENV-1 infection, the anti-DENV-2 activity observed for @entity4 _S381 was largely lost for the R381 variant. By allelic association study on a cohort of 740 @entity2 @entity0 , we found a protective effect of @entity4 _R381 against shock (OR=0.37; P<0.001). This effect was due to DENV-2 infections (OR=0.13, P=0.007), but was absent for DENV-1, in accordance with the serotype-dependent @entity4 activity found in the functional study. Severe @entity2 has long been associated with a "cytokine storm" of unclear origin. This work identifies an early innate immunity process that could lead to the immune overreaction observed in severe @entity2 , and triggered by a specific host genotype-pathogen genotype interaction.

title: High anti- XXXX viral activity of OAS gene family is associated with increased severity of dengue disease.

answer: @entity2


abstract: BACKGROUND AND AIMS: We previously demonstrated a significant @entity2 risk in @entity3 ( @entity3 ) @entity0 with mucosal changes indefinite for @entity5 (IND) and the potential diagnostic utility of @entity4 and @entity6 immunohistochemistry in @entity3 -associated @entity1 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity1 risk in the @entity3 -IND population. METHODS: We identified 44 eligible cases with @entity3 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity4 and @entity6 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity2 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity0 , 11 (25%) progressed to @entity1 (low-grade @entity5   =   6; high-grade @entity5   =   2; @entity1 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity4 overexpression were associated with progression to @entity1 . CONCLUSIONS: Twenty-five percent of @entity0 with @entity3 and IND developed @entity2 or @entity1 . Overexpression of @entity4 and age are associated with @entity1 progression.

title: Overexpression of XXXX predicts @entity2 risk in @entity0 with @entity3 and mucosa changes indefinite for @entity5 .

answer: @entity4


abstract: BACKGROUND AND AIMS: We previously demonstrated a significant @entity2 risk in @entity3 ( @entity3 ) @entity0 with mucosal changes indefinite for @entity5 (IND) and the potential diagnostic utility of @entity4 and @entity6 immunohistochemistry in @entity3 -associated @entity1 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity1 risk in the @entity3 -IND population. METHODS: We identified 44 eligible cases with @entity3 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity4 and @entity6 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity2 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity0 , 11 (25%) progressed to @entity1 (low-grade @entity5   =   6; high-grade @entity5   =   2; @entity1 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity4 overexpression were associated with progression to @entity1 . CONCLUSIONS: Twenty-five percent of @entity0 with @entity3 and IND developed @entity2 or @entity1 . Overexpression of @entity4 and age are associated with @entity1 progression.

title: Overexpression of @entity4 predicts @entity2 risk in @entity0 with XXXX and mucosa changes indefinite for @entity5 .

answer: @entity3


abstract: BACKGROUND AND AIMS: We previously demonstrated a significant @entity2 risk in @entity3 ( @entity3 ) @entity0 with mucosal changes indefinite for @entity5 (IND) and the potential diagnostic utility of @entity4 and @entity6 immunohistochemistry in @entity3 -associated @entity1 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity1 risk in the @entity3 -IND population. METHODS: We identified 44 eligible cases with @entity3 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity4 and @entity6 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity2 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity0 , 11 (25%) progressed to @entity1 (low-grade @entity5   =   6; high-grade @entity5   =   2; @entity1 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity4 overexpression were associated with progression to @entity1 . CONCLUSIONS: Twenty-five percent of @entity0 with @entity3 and IND developed @entity2 or @entity1 . Overexpression of @entity4 and age are associated with @entity1 progression.

title: Overexpression of @entity4 predicts @entity2 risk in @entity0 with @entity3 and mucosa changes indefinite for XXXX .

answer: @entity5


abstract: BACKGROUND AND AIMS: We previously demonstrated a significant @entity2 risk in @entity3 ( @entity3 ) @entity0 with mucosal changes indefinite for @entity5 (IND) and the potential diagnostic utility of @entity4 and @entity6 immunohistochemistry in @entity3 -associated @entity1 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity1 risk in the @entity3 -IND population. METHODS: We identified 44 eligible cases with @entity3 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity4 and @entity6 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity2 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity0 , 11 (25%) progressed to @entity1 (low-grade @entity5   =   6; high-grade @entity5   =   2; @entity1 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity4 overexpression were associated with progression to @entity1 . CONCLUSIONS: Twenty-five percent of @entity0 with @entity3 and IND developed @entity2 or @entity1 . Overexpression of @entity4 and age are associated with @entity1 progression.

title: Overexpression of @entity4 predicts XXXX risk in @entity0 with @entity3 and mucosa changes indefinite for @entity5 .

answer: @entity2


abstract: BACKGROUND AND AIMS: We previously demonstrated a significant @entity2 risk in @entity3 ( @entity3 ) @entity0 with mucosal changes indefinite for @entity5 (IND) and the potential diagnostic utility of @entity4 and @entity6 immunohistochemistry in @entity3 -associated @entity1 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity1 risk in the @entity3 -IND population. METHODS: We identified 44 eligible cases with @entity3 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity4 and @entity6 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity2 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity0 , 11 (25%) progressed to @entity1 (low-grade @entity5   =   6; high-grade @entity5   =   2; @entity1 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity4 overexpression were associated with progression to @entity1 . CONCLUSIONS: Twenty-five percent of @entity0 with @entity3 and IND developed @entity2 or @entity1 . Overexpression of @entity4 and age are associated with @entity1 progression.

title: Overexpression of @entity4 predicts @entity2 risk in XXXX with @entity3 and mucosa changes indefinite for @entity5 .

answer: @entity0


abstract: OBJECTIVE: To evaluate the efficacy and safety of electroacupuncture at Tianshu (ST25) for @entity0 with functional @entity2 (FC). METHODS: Ninety-six @entity0 with FC were randomized to receive deep needling on bilateral ST25 (group A, 48 cases) or shallow needling on bilateral ST25 (group B, 48 cases) with electroacupuncture once daily for 4 weeks. The proportion of @entity0 with four or more complete spontaneous bowel movements (CSBMs) per week, and scores of @entity2 symptoms and satisfaction with treatment were compared between two groups. Safety was also assessed. RESULTS: The proportion of @entity0 with four or more CSBMs per week was 52.1% in group A, significantly higher than 25.0% in group B during the 4-week treatment (P<0.05). The @entity2 symptom score of @entity0 were significantly improved in group A as compared with group B at week 2-4 (P<0.05). @entity0 in group A were more satisfied with their treatment compared with those in group B at week 1-4 (P<0.05). Five @entity0 in group A felt significant @entity1 and discomfort. No other adverse reaction was observed in both groups. CONCLUSION: Using electroacupuncture at ST25 to treat @entity0 with FC is effectively, and deep needling had more stable effect than shallow needling.

title: Efficacy of electroacupuncture in the treatment of functional XXXX : A randomized controlled pilot trial.

answer: @entity2


abstract: INTRODUCTION: There is reasonable evidence that @entity6 5-10 mg per week leads to reduction in @entity5 ( @entity8 ) @entity1 in @entity2 ( @entity2 ). However, this is based on studies conducted with lower @entity8 dosage than used currently. It is unclear whether higher doses of @entity6 may be better in reducing @entity1 . METHODS: This was a double-blind randomized controlled trial of 24 weeks duration. To be eligible, @entity0 should have @entity2 (1987 American College of Rheumatology criteria), be 18-75 years of age, not be on @entity8 and have active disease as defined by 'Modified Disease Activity Score using three variables' (DAS28(3)) > 3.2. @entity8 was started at 10 mg/week and escalated to 25 mg/week by 12 weeks. @entity6 was given at a dose of 10 mg (FA10) or 30 mg per week (FA30). Co-primary endpoints were incidence of @entity1 (undesirable symptoms and @entity4 ) and change in disease activity by 24 weeks. Intention-to-treat and per-protocol analyses were performed. RESULTS: Among 100 @entity0 enrolled, 51 and 49 were randomized to FA10 and FA30 respectively. By 24 weeks, there were 6 @entity0 withdrawals in either group and mean(  SD) dose of @entity8 was 22.8    4.4 and 21.4    4.6 mg per week (p = 0.1). Frequency of @entity0 with undesirable symptoms was non-significantly lower by 7.4 % (95 % confidence interval -27.4 to 12.7 %) in FA10 compared to FA30. There was also no difference in frequency of transaminitis (>Upper limit of normal (ULN)) (42.6, 45.7 %, p = 0.7) or transminitis as per primary endpoint (>2xULN) (10.6, 8.7 %, p = 1.0) or @entity7 (4.3, 4.3 %, p = 0.9). There was no difference in the primary end-point of occurrence of any adverse effect (symptom or laboratory) in FA10 and FA30 (46.8, 54.3 %, p = 0.5). At 24 weeks, DAS28(3) declined in both groups by a similar extent (-1.1    1.0, -1.3    1.0, p = 0.2) and 'European League Against @entity3 ' good or moderate response occurred in 56.9 and 67.4 % (p = 0.3). CONCLUSIONS: Even with the high doses of @entity8 used in current practice, there was no additional benefit (or harm) of a higher dose of @entity6 (30 mg/week) over a usual dose (10 mg/week). TRIAL REGISTRATION: Clinicaltrials.gov NCT01583959 Registered 15 March 2012.

title: Comparison of two different @entity6 doses with XXXX - a randomized controlled trial (FOLVARI Study).

answer: @entity5


abstract: INTRODUCTION: There is reasonable evidence that @entity6 5-10 mg per week leads to reduction in @entity5 ( @entity8 ) @entity1 in @entity2 ( @entity2 ). However, this is based on studies conducted with lower @entity8 dosage than used currently. It is unclear whether higher doses of @entity6 may be better in reducing @entity1 . METHODS: This was a double-blind randomized controlled trial of 24 weeks duration. To be eligible, @entity0 should have @entity2 (1987 American College of Rheumatology criteria), be 18-75 years of age, not be on @entity8 and have active disease as defined by 'Modified Disease Activity Score using three variables' (DAS28(3)) > 3.2. @entity8 was started at 10 mg/week and escalated to 25 mg/week by 12 weeks. @entity6 was given at a dose of 10 mg (FA10) or 30 mg per week (FA30). Co-primary endpoints were incidence of @entity1 (undesirable symptoms and @entity4 ) and change in disease activity by 24 weeks. Intention-to-treat and per-protocol analyses were performed. RESULTS: Among 100 @entity0 enrolled, 51 and 49 were randomized to FA10 and FA30 respectively. By 24 weeks, there were 6 @entity0 withdrawals in either group and mean(  SD) dose of @entity8 was 22.8    4.4 and 21.4    4.6 mg per week (p = 0.1). Frequency of @entity0 with undesirable symptoms was non-significantly lower by 7.4 % (95 % confidence interval -27.4 to 12.7 %) in FA10 compared to FA30. There was also no difference in frequency of transaminitis (>Upper limit of normal (ULN)) (42.6, 45.7 %, p = 0.7) or transminitis as per primary endpoint (>2xULN) (10.6, 8.7 %, p = 1.0) or @entity7 (4.3, 4.3 %, p = 0.9). There was no difference in the primary end-point of occurrence of any adverse effect (symptom or laboratory) in FA10 and FA30 (46.8, 54.3 %, p = 0.5). At 24 weeks, DAS28(3) declined in both groups by a similar extent (-1.1    1.0, -1.3    1.0, p = 0.2) and 'European League Against @entity3 ' good or moderate response occurred in 56.9 and 67.4 % (p = 0.3). CONCLUSIONS: Even with the high doses of @entity8 used in current practice, there was no additional benefit (or harm) of a higher dose of @entity6 (30 mg/week) over a usual dose (10 mg/week). TRIAL REGISTRATION: Clinicaltrials.gov NCT01583959 Registered 15 March 2012.

title: Comparison of two different XXXX doses with @entity5 - a randomized controlled trial (FOLVARI Study).

answer: @entity6


abstract: BACKGROUND: Generally, intracytoplasmic sperm injection (ICSI) may be the preferable method to treat @entity2 , but whether there exist some correlations between ICSI fertilization rate and the proportion of round-headed sperm or morphologically normal sperm remains open. This study was to explore the correlation between ICSI fertilization rate and the sperm morphology in @entity0 with @entity2 . METHODS: Thirty-four @entity0 diagnosed with @entity2 accepted the following assisted fertilization treatments - 2 cases accepted @entity1 ( @entity1 ) alone, 26 cases accepted ICSI alone, and 6 accepted split @entity1 /ICSI. Detailed morphological characteristics were described using Diff-Quik rapid staining. Sixty cases accepting @entity1 or ICSI treatment in our reproductive center were considered as the control group after being matched by relevant criteria. Fertilization rate, embryo quality, embryo implantation rate and clinical pregnancy rate were calculated. RESULTS: Besides very high proportion of round-headed sperm, @entity2 also showed very high proportion of small-acrosomal sperm and very low proportion of morphologically normal sperm. Fertilization rate of @entity1 ( @entity1 alone plus split @entity1 ) was very low in @entity2 (25.4%    17.4%), but ICSI (ICSI alone plus split ICSI) achieved satisfying fertilization rate compared with the control group (66.2%    22.5% vs. 68.8%    29.4%, P > 0.05). In @entity0 with @entity2 , there were no correlations between ICSI fertilization rate and the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm. CONCLUSIONS: There was high proportion of small-acrosomal sperm in @entity2 . For @entity0 with @entity2 , ICSI is more preferable than @entity1 . ICSI fertilization rate does not depend on the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm.

title: Intracytoplasmic Sperm Injection Fertilization Rate Does Not Depend on the Proportion of Round-headed Sperm, Small-acrosomal Sperm, or Morphologically Normal Sperm in @entity0 with XXXX .

answer: @entity2


abstract: BACKGROUND: Generally, intracytoplasmic sperm injection (ICSI) may be the preferable method to treat @entity2 , but whether there exist some correlations between ICSI fertilization rate and the proportion of round-headed sperm or morphologically normal sperm remains open. This study was to explore the correlation between ICSI fertilization rate and the sperm morphology in @entity0 with @entity2 . METHODS: Thirty-four @entity0 diagnosed with @entity2 accepted the following assisted fertilization treatments - 2 cases accepted @entity1 ( @entity1 ) alone, 26 cases accepted ICSI alone, and 6 accepted split @entity1 /ICSI. Detailed morphological characteristics were described using Diff-Quik rapid staining. Sixty cases accepting @entity1 or ICSI treatment in our reproductive center were considered as the control group after being matched by relevant criteria. Fertilization rate, embryo quality, embryo implantation rate and clinical pregnancy rate were calculated. RESULTS: Besides very high proportion of round-headed sperm, @entity2 also showed very high proportion of small-acrosomal sperm and very low proportion of morphologically normal sperm. Fertilization rate of @entity1 ( @entity1 alone plus split @entity1 ) was very low in @entity2 (25.4%    17.4%), but ICSI (ICSI alone plus split ICSI) achieved satisfying fertilization rate compared with the control group (66.2%    22.5% vs. 68.8%    29.4%, P > 0.05). In @entity0 with @entity2 , there were no correlations between ICSI fertilization rate and the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm. CONCLUSIONS: There was high proportion of small-acrosomal sperm in @entity2 . For @entity0 with @entity2 , ICSI is more preferable than @entity1 . ICSI fertilization rate does not depend on the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm.

title: Intracytoplasmic Sperm Injection Fertilization Rate Does Not Depend on the Proportion of Round-headed Sperm, Small-acrosomal Sperm, or Morphologically Normal Sperm in XXXX with @entity2 .

answer: @entity0


abstract: BACKGROUND: The incidence of @entity2 was studied more than 10 years ago in a small @entity0 cohort. Recent diagnostic advancements have improved the ability to detect this rare injury. HYPOTHESIS: The incidence of @entity2 will be significantly greater than previously reported. STUDY DESIGN: Descriptive epidemiologic study. METHODS: A query of the PearlDiver Technologies national database containing public and private insurance @entity0 was used to estimate the national incidence of @entity2 in the United States. A retrospective chart review of our local population identified demographic groups and risk factors that increased likelihood of injury. RESULTS: The estimated national incidence of @entity2 was 2.55 per 100,000 @entity0 -years. The local incidence was 5.35 per 100,000 @entity0 -years. The mean and median ages of @entity0 in our regional cohort were 46.3 and 46 years, respectively. Males composed the majority of the injured population (national 95%, regional 96%). Smoking and elevated body mass index were found to be associated with increased likelihood of @entity1 showed no association. CONCLUSION: The incidence of @entity2 in this study was higher than previously reported.

title: XXXX : An Epidemiological Analysis Using a Large Population Database.

answer: @entity2


abstract: INTRODUCTION: Transcatheter arterial chemoembolization (TACE) plus thermal ablation has been widely used recently in the treatment of @entity2 ( @entity2 ). In this study, we aimed to compare results of the combination of TACE and percutaneous thermal ablation with those of hepatectomy in @entity0 with @entity2 . METHODS: The clinical data of 137 @entity2 @entity0 who sequentially received TACE and computed tomography (CT)-guided percutaneous thermal ablation as an initial curative treatment (combination group) and 148 matched @entity2 @entity0 who received hepatectomy (surgery group) between 2004 and 2011 were collected and analyzed. After TACE, multiphase contrast-enhanced CT was performed to identify the total number of @entity1 as well as @entity3 deposition in the liver. Survival was calculated by using the Kaplan-Meier method and compared by using the log-rank test. The prognostic factors were assessed with multivariate Cox proportional hazards regression analysis. RESULTS: Of all 285 @entity0 , 225 (79.0  %) had @entity1    <=   5  cm in diameter. In preoperative contrast-enhanced CT or magnetic resonance imaging, the number of @entity1 was 1-4 for each @entity0 . The 1-, 3-, and 5-year overall survival rates were 95, 74  %, and 67  % in the combination group and 88, 66, and 47  % in the surgery group, respectively (P   =   0.004); the corresponding recurrence-free survival rates for the two groups were 92, 69, and 61  % and 75, 58, and 44  %, respectively (P   =   0.001). In the multivariate analysis, treatment allocation was an independent prognostic factor for survival. Only 60 @entity0 in the combination group had sufficient imaging data, and 135 new lesions with @entity3 deposition were diagnosed as @entity1 in 22 of 60 @entity0 , whereas 20 new lesions were found in 11 of 148 @entity0 in the surgery group. CONCLUSION: The combination of TACE and CT-guided percutaneous thermal ablation for @entity2 improves survival of @entity2 @entity0 compared with hepatectomy.

title: Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of XXXX .

answer: @entity2


abstract: BACKGROUND: The management of advanced @entity1 ( @entity1 ) has recently changed. We assessed the activity of @entity3 after failure of other systemic treatments in advanced @entity1 . METHODS: This was a multicenter, open-label, phase II study evaluating @entity3 as a single agent in advanced @entity1 (PAZONET study). The clinical benefit rate (CBR) at 6 months was the primary end point. Translational correlation of radiological response and progression-free survival (PFS) with circulating and tissue biomarkers was also evaluated. RESULTS: A total of 44 @entity0 were enrolled. Twenty-five @entity0 (59.5%) were progression-free at 6 months (4 partial responses, 21 stable diseases) with a median PFS of 9.5 months [95% confidence interval (CI) 4.8-14.1]. The CBR varied according to prior therapy received, with 73%, 60% and 25% in @entity0 treated with prior multitarget inhibitors, prior @entity2 inhibitors and both agents, respectively. A nonsignificant increase in PFS was observed in @entity0 presenting lower baseline circulating @entity1 cell (CTC) counts (9.1 versus 5.8 months; P = 0.22) and in those with decreased levels of soluble-vascular endothelial growth factor receptor-2 (sVEGFR-2) (12.6 versus 9.1 months; P = 0.067). A trend toward reduced survival was documented in @entity0 with @entity4 @entity6 and @entity5 missense polymorphisms [hazard ratio (HR): 12.3; 95% CI 1.09-139.2; P = 0.042 and HR: 6.9; 95% CI 0.96-49.9; P = 0.055, respectively]. CONCLUSIONS: @entity3 showed clinical activity in @entity0 with advanced @entity1 regardless of previous treatments. Additionally, CTCs, soluble-s VEFGR-2 and @entity4 gene polymorphisms constitute potential biomarkers for selecting @entity0 for @entity3 (NCT01280201). CLINICAL TRIAL NUMBER: NCT01280201.

title: @entity3 in XXXX : a phase II, open-label trial of the Spanish Task Force Group for @entity1 (GETNE)   .

answer: @entity1


abstract: BACKGROUND: The management of advanced @entity1 ( @entity1 ) has recently changed. We assessed the activity of @entity3 after failure of other systemic treatments in advanced @entity1 . METHODS: This was a multicenter, open-label, phase II study evaluating @entity3 as a single agent in advanced @entity1 (PAZONET study). The clinical benefit rate (CBR) at 6 months was the primary end point. Translational correlation of radiological response and progression-free survival (PFS) with circulating and tissue biomarkers was also evaluated. RESULTS: A total of 44 @entity0 were enrolled. Twenty-five @entity0 (59.5%) were progression-free at 6 months (4 partial responses, 21 stable diseases) with a median PFS of 9.5 months [95% confidence interval (CI) 4.8-14.1]. The CBR varied according to prior therapy received, with 73%, 60% and 25% in @entity0 treated with prior multitarget inhibitors, prior @entity2 inhibitors and both agents, respectively. A nonsignificant increase in PFS was observed in @entity0 presenting lower baseline circulating @entity1 cell (CTC) counts (9.1 versus 5.8 months; P = 0.22) and in those with decreased levels of soluble-vascular endothelial growth factor receptor-2 (sVEGFR-2) (12.6 versus 9.1 months; P = 0.067). A trend toward reduced survival was documented in @entity0 with @entity4 @entity6 and @entity5 missense polymorphisms [hazard ratio (HR): 12.3; 95% CI 1.09-139.2; P = 0.042 and HR: 6.9; 95% CI 0.96-49.9; P = 0.055, respectively]. CONCLUSIONS: @entity3 showed clinical activity in @entity0 with advanced @entity1 regardless of previous treatments. Additionally, CTCs, soluble-s VEFGR-2 and @entity4 gene polymorphisms constitute potential biomarkers for selecting @entity0 for @entity3 (NCT01280201). CLINICAL TRIAL NUMBER: NCT01280201.

title: @entity3 in @entity1 : a phase II, open-label trial of the Spanish Task Force Group for XXXX (GETNE)   .

answer: @entity1


abstract: BACKGROUND: The management of advanced @entity1 ( @entity1 ) has recently changed. We assessed the activity of @entity3 after failure of other systemic treatments in advanced @entity1 . METHODS: This was a multicenter, open-label, phase II study evaluating @entity3 as a single agent in advanced @entity1 (PAZONET study). The clinical benefit rate (CBR) at 6 months was the primary end point. Translational correlation of radiological response and progression-free survival (PFS) with circulating and tissue biomarkers was also evaluated. RESULTS: A total of 44 @entity0 were enrolled. Twenty-five @entity0 (59.5%) were progression-free at 6 months (4 partial responses, 21 stable diseases) with a median PFS of 9.5 months [95% confidence interval (CI) 4.8-14.1]. The CBR varied according to prior therapy received, with 73%, 60% and 25% in @entity0 treated with prior multitarget inhibitors, prior @entity2 inhibitors and both agents, respectively. A nonsignificant increase in PFS was observed in @entity0 presenting lower baseline circulating @entity1 cell (CTC) counts (9.1 versus 5.8 months; P = 0.22) and in those with decreased levels of soluble-vascular endothelial growth factor receptor-2 (sVEGFR-2) (12.6 versus 9.1 months; P = 0.067). A trend toward reduced survival was documented in @entity0 with @entity4 @entity6 and @entity5 missense polymorphisms [hazard ratio (HR): 12.3; 95% CI 1.09-139.2; P = 0.042 and HR: 6.9; 95% CI 0.96-49.9; P = 0.055, respectively]. CONCLUSIONS: @entity3 showed clinical activity in @entity0 with advanced @entity1 regardless of previous treatments. Additionally, CTCs, soluble-s VEFGR-2 and @entity4 gene polymorphisms constitute potential biomarkers for selecting @entity0 for @entity3 (NCT01280201). CLINICAL TRIAL NUMBER: NCT01280201.

title: XXXX in @entity1 : a phase II, open-label trial of the Spanish Task Force Group for @entity1 (GETNE)   .

answer: @entity3


abstract: BACKGROUND AND AIMS: Restorative proctocolectomy is the most common operation in @entity0 with @entity2 . The aim was to evaluate long-term changes in our operative treatment and early and late complications related to restorative proctocolectomy. MATERIAL AND METHODS: The study comprised 352 (149 females) @entity0 over 18   years of age with @entity2 who underwent restorative proctocolectomy in 1985-2009 median follow-up time of 5   years. RESULTS: The indication for surgery was active @entity5 in 168 (47.7%), @entity5 in 159 (45.2%), and @entity1 or @entity4 in 25 (7.1%) @entity0 . Ileal pouch-anal @entity3 was performed using hand-sewn @entity3 with mucosectomy in 283 @entity0 and stapled @entity3 in 69. A shift from hand-sewn to stapler ileal pouch-anal @entity3 took place in 2005. Covering ileostomy was carried out in 133 (37.8%) @entity0 . There were 82 (23.3%) J-pouch-related complications. The operative mortality was 0.3%. There were significantly fewer leakages and early re-operations when covering ileostomy was used than when it was omitted: 6.0% versus 16.4% (p   =   0.004), 4.5% versus 11.9% (p   =   0.02), respectively. There were more strictures in hand-sewn than in stapled ileal pouch-anal anastomoses (17.6% vs. 0%, p   =   0.001). @entity6 occurred at least once in 134 (38.1%) @entity0 . CONCLUSION: The ileal pouch-anal @entity3 technique used in restorative proctocolectomy had changed over the past years from hand-sewn to stapled @entity3 . Covering ileostomy seemed to protect against major complications. @entity6 was the most common late complication.

title: Restorative proctocolectomy for XXXX IN 1985-2009.

answer: @entity2


abstract: BACKGROUND: @entity1 control rates remain suboptimal. Pharmacists' scope of practice is evolving, and their position in the community may be ideal for improving @entity1 care. We aimed to study the impact of pharmacist prescribing on blood pressure (BP) control in community-dwelling @entity0 . METHODS AND RESULTS: We designed a @entity0 -level, randomized, controlled trial, enrolling adults with above-target BP (as defined by Canadian guidelines) through community pharmacies, hospitals, or primary care teams in 23 communities in Alberta. Intervention group @entity0 received an assessment of BP and cardiovascular risk, education on @entity1 , prescribing of antihypertensive medications, laboratory monitoring, and monthly follow-up visits for 6 months (all by their pharmacist). Control group @entity0 received a wallet card for BP recording, written @entity1 information, and usual care from their pharmacist and physician. Primary outcome was the change in systolic BP at 6 months. A total of 248 @entity0 (mean age, 64 years; 49% male) were enrolled. Baseline mean  SD systolic/diastolic BP was 150  14/84  11 mm Hg. The intervention group had a mean  @entity2 at 6 months of 18.3  1.2 compared with 11.8  1.9 mm Hg in the control group, an adjusted difference of 6.6  1.9 mm Hg (P=0.0006). The adjusted odds of @entity0 achieving BP targets was 2.32 (95% confidence interval, 1.17-4.15 in favor of the intervention). CONCLUSIONS: Pharmacist prescribing for @entity0 with @entity1 resulted in a clinically important and statistically significant reduction in BP. Policy makers should consider an expanded role for pharmacists, including prescribing, to address the burden of @entity1 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00878566.

title: Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing XXXX (RxACTION).

answer: @entity1


abstract: It is still a matter of debate as to which parameters should be used for noninvasive diagnosis of @entity3 by @entity1 ( @entity1 ). The accuracy of @entity1 in the detection of @entity4 ( @entity4 ) was tested in 95 consecutive, moderate to severe @entity2 @entity0 (I-II World Health Organization [WHO] stages). Reno-aortic ratio (RAR) for peak systolic velocity (PSV) was also calculated to assist in the diagnosis of significant (>50%) @entity4 . Paired receiver-operating characteristic (ROC) analysis was plotted for evaluating the relationship between sensitivity and specificity for each parameter. In a subset of 57 kidneys, the influence of blood pressure and age on intraparenchymal parameters was evaluated. Measurements of maximal peak systolic velocity (PSV) at the site of stenosis, RAR for PSV, and minimum acceleration index in the main renal artery showed high accuracy (areas under the ROC curve 0.97, 0.88, and 0.80, respectively). Among intraparenchymal parameters, early systolic acceleration showed the best area under the ROC curve (0.90), but provided a low positive predictive value (29%) and was significantly influenced by blood pressure (multiple r=0.56; p=0.001). Pulsatility and resistive indices were found to be less powerful as absolute values, and both significantly influenced by blood pressure and age (multiple r=0.60 and 0.50; p=0.001, p=0.02, respectively). However, interindividual variance of intrarenal indices should be minimized by calculation of side difference, although this procedure would become misleading or impossible in @entity0 with bilateral @entity4 or a single kidney, respectively. These results support the use of extraparenchymal parameters for noninvasive detection of @entity4 , and emphasize that intrarenal parameters cannot be considered as absolute values.

title: Diagnosis of XXXX by extra- and intrarenal Doppler parameters.

answer: @entity3


abstract: The aim of this study was to characterize a novel animal model @entity1 -induced @entity2 and to investigate the impacts of repetitive @entity2 on @entity4 performances in immature @entity0 . Methods. @entity0 were subjected to @entity1 exposure one, two, or three times in 10-day intervals during 30   min in a water bath warmed at 45-50  C and their behaviour was monitored. Morris water maze @entity4 were examined for control and treated groups. Results showed that @entity0 subjected to 30-minute @entity1 hot water developed rapidly @entity3 and then generalized @entity2 . After a single @entity1 exposure, the time for generalised @entity2 appearance was 16.08    0.60   min and it decreased gradually with repetitive exposure to reach 12.46    0.39   min by the third exposure. @entity2 altered the @entity4 abilities in Morris water maze and increased the time spent to attain the platform after one or two exposures, while after a third exposure @entity0 exhibited the same latency compared to controls. Similar results were obtained in probe test where @entity0 , subjected to @entity1 for one or two episodes, spent less time in the target quadrant compared to corresponding controls. Further, when platform was moved from northwest to southwest quadrant, memory transfer test indicated that after one or two @entity1 exposures cognitive performances were slightly altered, while after a third exposure the latency to escape increased significantly compared to untreated group. It was concluded that 30   min of @entity1 hot water was sufficient to induce @entity2 in immature @entity0 and an increase of susceptibility was observed with repetitive @entity1 exposure. @entity1 treatment impaired cognitive performances but the effects were mostly transient and moderate.

title: XXXX Have Moderate and Transient Effects on Spatial Learning in Immature @entity0 .

answer: @entity2


abstract: The aim of this study was to characterize a novel animal model @entity1 -induced @entity2 and to investigate the impacts of repetitive @entity2 on @entity4 performances in immature @entity0 . Methods. @entity0 were subjected to @entity1 exposure one, two, or three times in 10-day intervals during 30   min in a water bath warmed at 45-50  C and their behaviour was monitored. Morris water maze @entity4 were examined for control and treated groups. Results showed that @entity0 subjected to 30-minute @entity1 hot water developed rapidly @entity3 and then generalized @entity2 . After a single @entity1 exposure, the time for generalised @entity2 appearance was 16.08    0.60   min and it decreased gradually with repetitive exposure to reach 12.46    0.39   min by the third exposure. @entity2 altered the @entity4 abilities in Morris water maze and increased the time spent to attain the platform after one or two exposures, while after a third exposure @entity0 exhibited the same latency compared to controls. Similar results were obtained in probe test where @entity0 , subjected to @entity1 for one or two episodes, spent less time in the target quadrant compared to corresponding controls. Further, when platform was moved from northwest to southwest quadrant, memory transfer test indicated that after one or two @entity1 exposures cognitive performances were slightly altered, while after a third exposure the latency to escape increased significantly compared to untreated group. It was concluded that 30   min of @entity1 hot water was sufficient to induce @entity2 in immature @entity0 and an increase of susceptibility was observed with repetitive @entity1 exposure. @entity1 treatment impaired cognitive performances but the effects were mostly transient and moderate.

title: @entity2 Have Moderate and Transient Effects on Spatial Learning in Immature XXXX .

answer: @entity0


abstract: Acute rejection is a major risk factor for @entity2 ( @entity2 ). Blood leukocytes interacting with allograft endothelial cells during acute rejection were suggested to contribute to the still enigmatic pathogenesis of @entity2 . We hypothesize that tissue transglutaminase ( @entity4 ), a multifunctional protein and established marker of M2 macrophages, is involved in acute and chronic graft rejection. We focus on leukocytes accumulating in blood vessels of @entity0 renal allografts (Fischer-344 to Lewis), an established model for reversible acute rejection and @entity2 . Monocytes in graft blood vessels overexpress @entity4 when acute rejection peaks on day 9 after transplantation. Concomitantly, @entity1 is activated, suggesting that @entity4 expression is linked to apoptosis. After resolution of acute rejection on day 42, leukocytic @entity4 levels are lower and activated @entity1 does not differ among isografts and allografts. @entity3 was applied for 4 weeks after transplantation to inhibit extracellular transglutaminase activity, which did, however, not reduce @entity2 in the long run. In conclusion, this is the first report on @entity4 expression by monocytes in vivo. @entity4 may be involved in leukocytic apoptosis and thus in reversion of acute rejection. However, our data do not support a role of extracellular transglutaminase activity as a factor triggering @entity2 during self-limiting acute rejection.

title: Monocytic Tissue Transglutaminase in a XXXX Model for Reversible Acute Rejection and Chronic Renal Allograft Injury.

answer: @entity0


abstract: BACKGROUND AND PURPOSE: We sought to determine the incidence of recurrent @entity3 in @entity0 in the Asymptomatic @entity6 Study (ACAS) who had undergone carotid endarterectomy and were prospectively followed with Doppler ultrasound for up to 5 years. METHODS: The ACAS database was interrogated to determine the rate of recurrent @entity3 (>/=60%) based up angiogram-validated Doppler data, with a 90% and a 95% positive predictive value, as well as information concerning the technologists' interpretation of percent @entity4 . These 3 parameters are reported for each of 3 time intervals: within 3 months of operation ( @entity2 ), between 3 and 18 months (early restenoses), and between 18 and 60 months (late restenosis). RESULTS: Of the 825 @entity0 randomized to the surgical arm of the study, 720 actually underwent carotid endarterectomy, and 645 had complete ultrasound data. The aggregate incidence of residual and recurrent @entity3 for all time intervals ranged from 12.7% to 20.4%, depending on the positive predictive value confidence level desired. @entity2 occurred in 4.1% to 6.5%; true, early restenosis was found in 7.6% to 11.4%; and late restenosis occurred in 1.9% to 4.9%. None of the traditional risk factors showed a statistically significant effect on recurrent @entity4 . The use of patch angioplasty closure reduced overall risk of restenosis from 21.2% to 7.1%, from 16.7% to 4.6%, and from 27.4% to 8.2%, depending on the @entity5 confidence level desired (P<0.001). Of the 136 @entity0 judged to have recurrent @entity4 , only 8 (5.9%) underwent reoperation (only 1 for symptoms). There was no correlation between late @entity1 and recurrent @entity4 . CONCLUSIONS: Carotid endarterectomy is a durable procedure with a low rate of true restenosis, particularly when patch angioplasty is used to close the arteriotomy.

title: Recurrent XXXX : results of the asymptomatic @entity6 study.

answer: @entity3


abstract: BACKGROUND AND PURPOSE: We sought to determine the incidence of recurrent @entity3 in @entity0 in the Asymptomatic @entity6 Study (ACAS) who had undergone carotid endarterectomy and were prospectively followed with Doppler ultrasound for up to 5 years. METHODS: The ACAS database was interrogated to determine the rate of recurrent @entity3 (>/=60%) based up angiogram-validated Doppler data, with a 90% and a 95% positive predictive value, as well as information concerning the technologists' interpretation of percent @entity4 . These 3 parameters are reported for each of 3 time intervals: within 3 months of operation ( @entity2 ), between 3 and 18 months (early restenoses), and between 18 and 60 months (late restenosis). RESULTS: Of the 825 @entity0 randomized to the surgical arm of the study, 720 actually underwent carotid endarterectomy, and 645 had complete ultrasound data. The aggregate incidence of residual and recurrent @entity3 for all time intervals ranged from 12.7% to 20.4%, depending on the positive predictive value confidence level desired. @entity2 occurred in 4.1% to 6.5%; true, early restenosis was found in 7.6% to 11.4%; and late restenosis occurred in 1.9% to 4.9%. None of the traditional risk factors showed a statistically significant effect on recurrent @entity4 . The use of patch angioplasty closure reduced overall risk of restenosis from 21.2% to 7.1%, from 16.7% to 4.6%, and from 27.4% to 8.2%, depending on the @entity5 confidence level desired (P<0.001). Of the 136 @entity0 judged to have recurrent @entity4 , only 8 (5.9%) underwent reoperation (only 1 for symptoms). There was no correlation between late @entity1 and recurrent @entity4 . CONCLUSIONS: Carotid endarterectomy is a durable procedure with a low rate of true restenosis, particularly when patch angioplasty is used to close the arteriotomy.

title: Recurrent @entity3 : results of the asymptomatic XXXX study.

answer: @entity6


abstract: The proliferative response of clonal B cells from @entity0 with @entity2 ( @entity2 ) is drastically reduced compared to normal B lymphocytes stimulated via the B cell antigen receptor complex or by @entity7 ligation. In the present study we demonstrate that @entity10 of CLL-B cells can be overcome by stimulatory pathways mediated by activated @entity1 (+) T cells. In contrast to @entity7 ligation, costimulation with activated T cells promotes a proliferative response in CLL-B cells identical to that in normal B cells. Furthermore, coculture with activated T cells improved survival of CLL-B cells in vitro. Differentiation of CLL-B cells into IgM producing cells was promoted, as well. However, the capacity for IgM secretion remained impaired compared to that of normal B cells. For T-cell-mediated B cell activation direct cellular contact with activated T helper cells is absolutely required. Prevention of @entity7 / @entity12 interaction by @entity7 antibody caused only partial inhibition of B cell activation, suggesting that additional signals are involved in T-B cell interaction. Whereas interruption of the ligand pairs @entity4 / @entity5 , @entity9 / @entity14 , @entity6 / @entity13 had no influence, the addition of @entity11 antibody completely inhibited B cell activation by activated T cells. In costimulation with cellular signals the presence of B-cell-tropic cytokines, such as @entity3 and @entity8 , was required to optimize @entity2 proliferation, as demonstrated by the use of neutralizing antibodies. We conclude from these results that proliferative @entity10 by CLL-B cells can be circumvented by antigen-nonspecific signals in addition to @entity7 which are mediated by direct contact with activated T helper cells.

title: Direct cellular interaction with activated @entity1 (+) T cells overcomes @entity10 of XXXX in vitro.

answer: @entity2


abstract: The proliferative response of clonal B cells from @entity0 with @entity2 ( @entity2 ) is drastically reduced compared to normal B lymphocytes stimulated via the B cell antigen receptor complex or by @entity7 ligation. In the present study we demonstrate that @entity10 of CLL-B cells can be overcome by stimulatory pathways mediated by activated @entity1 (+) T cells. In contrast to @entity7 ligation, costimulation with activated T cells promotes a proliferative response in CLL-B cells identical to that in normal B cells. Furthermore, coculture with activated T cells improved survival of CLL-B cells in vitro. Differentiation of CLL-B cells into IgM producing cells was promoted, as well. However, the capacity for IgM secretion remained impaired compared to that of normal B cells. For T-cell-mediated B cell activation direct cellular contact with activated T helper cells is absolutely required. Prevention of @entity7 / @entity12 interaction by @entity7 antibody caused only partial inhibition of B cell activation, suggesting that additional signals are involved in T-B cell interaction. Whereas interruption of the ligand pairs @entity4 / @entity5 , @entity9 / @entity14 , @entity6 / @entity13 had no influence, the addition of @entity11 antibody completely inhibited B cell activation by activated T cells. In costimulation with cellular signals the presence of B-cell-tropic cytokines, such as @entity3 and @entity8 , was required to optimize @entity2 proliferation, as demonstrated by the use of neutralizing antibodies. We conclude from these results that proliferative @entity10 by CLL-B cells can be circumvented by antigen-nonspecific signals in addition to @entity7 which are mediated by direct contact with activated T helper cells.

title: Direct cellular interaction with activated XXXX (+) T cells overcomes @entity10 of @entity2 in vitro.

answer: @entity1


abstract: The proliferative response of clonal B cells from @entity0 with @entity2 ( @entity2 ) is drastically reduced compared to normal B lymphocytes stimulated via the B cell antigen receptor complex or by @entity7 ligation. In the present study we demonstrate that @entity10 of CLL-B cells can be overcome by stimulatory pathways mediated by activated @entity1 (+) T cells. In contrast to @entity7 ligation, costimulation with activated T cells promotes a proliferative response in CLL-B cells identical to that in normal B cells. Furthermore, coculture with activated T cells improved survival of CLL-B cells in vitro. Differentiation of CLL-B cells into IgM producing cells was promoted, as well. However, the capacity for IgM secretion remained impaired compared to that of normal B cells. For T-cell-mediated B cell activation direct cellular contact with activated T helper cells is absolutely required. Prevention of @entity7 / @entity12 interaction by @entity7 antibody caused only partial inhibition of B cell activation, suggesting that additional signals are involved in T-B cell interaction. Whereas interruption of the ligand pairs @entity4 / @entity5 , @entity9 / @entity14 , @entity6 / @entity13 had no influence, the addition of @entity11 antibody completely inhibited B cell activation by activated T cells. In costimulation with cellular signals the presence of B-cell-tropic cytokines, such as @entity3 and @entity8 , was required to optimize @entity2 proliferation, as demonstrated by the use of neutralizing antibodies. We conclude from these results that proliferative @entity10 by CLL-B cells can be circumvented by antigen-nonspecific signals in addition to @entity7 which are mediated by direct contact with activated T helper cells.

title: Direct cellular interaction with activated @entity1 (+) T cells overcomes XXXX of @entity2 in vitro.

answer: @entity10


abstract: OBJECTIVES: The main purpose of this study was to demonstrate an increase in the wettability of @entity0 -based impression materials after coating them with a hydrophilic film in a glow-discharge system. METHODS: Two @entity3 impression materials, Extrude (Kerr) and Accuflex (GC America Inc.) were used. Impression specimens were treated in a glow-discharge reactor at a radio frequency of 13.56 MHz at different discharge powers (5-20 W) and exposure times (5-60 min). Surface analysis of the specimens was done by FTIR. Surface contact angles were obtained by a captive-bubble method. These results were analyzed by ANOVA and Duncan's Multiple Range test (p < 0.05). The total number of voids on the die stone casts was observed microscopically. Linear dimensional accuracy, detail reproducibility, and surface @entity1 of the die stone casts were also determined. A Student t-test was performed for statistical analysis of these parameters (p > 0.05). RESULTS: FTIR spectra indicated that the number of @entity2 groups on the surfaces increased (p > 0.05) because of the glow-discharge treatment. Contact angle measurements showed an increase (p < 0.05) in surface hydrophilicity. Total void formation in the stone casts decreased. There were no significant differences in the linear dimensional accuracy, detail reproducibility, and @entity1 , before and after glow-discharge treatment (p > 0.05). SIGNIFICANCE: It was concluded that the surface wettability of the impression materials may be increased by plasma deposition, and therefore, the formation of voids was reduced in the stone casts.

title: Coating of XXXX -based impression materials in a glow-discharge system by acrylic acid plasma.

answer: @entity0


abstract: BACKGROUND: Though a rare clinical entity, anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) a common cause of @entity8 in @entity0 . Unrecognized and untreated it leads to progressive @entity14 and @entity4 . In settings of high infectious burden, ALCAPA may erroneously be diagnosed as @entity13 , @entity6 or other common childhood disorders. CLINICAL CASE: We present the case of a 10 weeks old male @entity0 who presented to the inpatient unit with marked @entity12 and @entity3 . He was inconsolable, had marked @entity9 , cool extremities, central and peripheral cyanosis @entity1 . The radial and brachial pulses were absent. The mean arterial pressure was 65mmHg, Heart rate of 160 beats per minute with a third heart sound. The liver was enlarged 4cm below the costal margin and tender, with a @entity5 . He had an elevated @entity11 Kinase-MB of 112.5 u/L. ECG revealed deep Q waves in leads I, aVL, V5, V6 with ST elevation in the anterolateral leads. Echo showed a dilated left ventricle LVEDd of 40mm, with paradoxical interventricular septal motion, severe @entity4 (FS=15%, EF=28%), LV anterolateral wall echo brightness and flow reversal in the Left coronary artery with its origin from the pulmonary trunk. He was admitted to the coronary care unit as a case of @entity8 with @entity2 . He received fluid resuscitation, inotropic support and standard management of @entity10 . Six days later he was discharged home with a plan to refer abroad. He died at home after one week. CONCLUSION: A combination of a high index of suspicion, typical ECG and echocardiographic findings in a young @entity0 presenting with @entity7 could lead to an earlier diagnosis of ALCAPA.

title: A case of anomalous origin of the left coronary artery presenting with @entity8 and XXXX .

answer: @entity2


abstract: BACKGROUND: Though a rare clinical entity, anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) a common cause of @entity8 in @entity0 . Unrecognized and untreated it leads to progressive @entity14 and @entity4 . In settings of high infectious burden, ALCAPA may erroneously be diagnosed as @entity13 , @entity6 or other common childhood disorders. CLINICAL CASE: We present the case of a 10 weeks old male @entity0 who presented to the inpatient unit with marked @entity12 and @entity3 . He was inconsolable, had marked @entity9 , cool extremities, central and peripheral cyanosis @entity1 . The radial and brachial pulses were absent. The mean arterial pressure was 65mmHg, Heart rate of 160 beats per minute with a third heart sound. The liver was enlarged 4cm below the costal margin and tender, with a @entity5 . He had an elevated @entity11 Kinase-MB of 112.5 u/L. ECG revealed deep Q waves in leads I, aVL, V5, V6 with ST elevation in the anterolateral leads. Echo showed a dilated left ventricle LVEDd of 40mm, with paradoxical interventricular septal motion, severe @entity4 (FS=15%, EF=28%), LV anterolateral wall echo brightness and flow reversal in the Left coronary artery with its origin from the pulmonary trunk. He was admitted to the coronary care unit as a case of @entity8 with @entity2 . He received fluid resuscitation, inotropic support and standard management of @entity10 . Six days later he was discharged home with a plan to refer abroad. He died at home after one week. CONCLUSION: A combination of a high index of suspicion, typical ECG and echocardiographic findings in a young @entity0 presenting with @entity7 could lead to an earlier diagnosis of ALCAPA.

title: A case of anomalous origin of the left coronary artery presenting with XXXX and @entity2 .

answer: @entity8


abstract: BACKGROUND/OBJECTIVES: Dietary pattern and its association with @entity2 have not been studied in Baoji city by now. This study was aimed to identify the dietary patterns among Chinese adults in Baoji, and explore the association between these dietary patterns and @entity2 . SUBJECTS/METHODS: A total of 4,968 @entity0 were included in this study at 12 counties. With multistage stratified random sampling and semi quantitative food frequency questionnaire, the prevalence of @entity2 and dietary intake were investigated in 2013. We used factor analysis to establish dietary patterns. RESULTS: A total of 4,968 @entity0 over 15 years old were included in this study. Five dietary patterns were identified in Baoji: protein, balanced, beans, prudent, and traditional patterns. The protein dietary pattern mainly included animal and plant proteins and was negatively associated with @entity3 as well as @entity1 . The balanced pattern included @entity5 , protein, and fat and was negatively associated with @entity3 as well as @entity1 . The beans pattern was mainly beans and beans products and was negatively associated with @entity3 . The prudent pattern only included staple foods and pickled vegetables and was positively associated with @entity3 as well as @entity4 . The traditional pattern was representative of local Baoji traditional recipes and was positively associated with @entity3 . CONCLUSIONS: The protein, balanced, and beans dietary patterns showed many protective effects on @entity2 . Based on these results, Baoji city residents should be encouraged to choose protein, balanced, and beans dietary patterns and abandon prudent and traditional patterns to prevent incidence of @entity3 , @entity4 , and @entity1 .

title: Dietary patterns and XXXX in a Chinese population.

answer: @entity2


abstract: BACKGROUND: Female @entity1 , especially breast and gynecologic @entity1 are considered multistage disease, highly influenced by risk and protective factors and/or screening preventive modalities. Consequences of all these factors result in the trend of change over time. METHODS: In this comparative study, based on data of national @entity1 registry of Iran 2004 published by Iranian Ministry of Health, age - standard incidence rate (ASR) according to the world population was calculated in all reported gynecologic and @entity0 . Source of all subjects are pathologic based. In the next step, the calculated ASR of Iran and those of the other countries in 2004 were compared to GLOBOCAN ASR reports of 2008. RESULTS: In Iran ASR of @entity0 2004 (24.93) changed to 18.4 in 2008. @entity2 ASR of 2004, 3.07 was 3.1 in 2008. @entity3 ASR in 2004 (2.29) was 1.7 in 2008. @entity1 ASR of 1.71 in 2004 was 2.2 in 2008. CONCLUSIONS: In Iran incidence trend of breast and endometrium are decreasing in the same direction of USA and Australia. Increasing trend of ovary and cervix ASR in Iran is in the inverse direction of USA and Australia which are decreasing. Future studies to find out the same trend or any changes, might develop these findings and improve consequent practical decisions based on results of this study and complementary future studies.

title: Comparison of Age- Standard Incidence Rate Trends of Gynecologic and XXXX in Iran and Other Countries.

answer: @entity0